Eli Lilly and Company controversies

Controversies tied to this brand in public sources. A listing is not a finding of fault.

2026
Pennsylvania sues insulin makers and PBMs over alleged insulin price collusion
Lawsuit filed
Pennsylvania filed a lawsuit against Eli Lilly and Company, Novo Nordisk Inc., Sanofi-Aventis US LLC, and several pharmacy benefit managers (PBMs), alleging that the companies colluded to raise insulin prices. The suit seeks structural changes, restitution, and financial penalties. The allegations concern the pricing of insulin and the roles of both manufacturers and PBMs. The case is a civil action brought by the state; the filing does not itself establish liability, and the claims remain allegations to be resolved through legal proceedings.
Pennsylvania sued Eli Lilly and Co., Novo Nordisk Inc., Sanofi-Aventis US LLC, and several PBMs, alleging that they colluded to raise insulin prices. The lawsuit seeks structural changes, restitution, and financial penalties.
Source excerpt
- Last week, Pennsylvania sued a group of pharmaceutical companies and PBMs for allegedly colluding to raise insulin prices unnecessarily.
- The pharmaceutical companies included in the Pennsylvania case are Eli Lilly and Co., Novo Nordisk Inc., and Sanofi-Aventis US LLC. Several PBMs are included as defendants, including Express Scripts, Caremark, and Optum RX.
- The state’s lawsuit seeks to institute “structural changes to ensure the companies lower costs to fair market prices and enable options for patients,” restitution for Pennsylvanians harmed by the scheme, and payments including financial penalties paid by the companies and the costs of the state’s investigation and lawsuit.
Source
2025
Indiana sues Eli Lilly over alleged insulin price-fixing
Lawsuit filed
Indiana filed a lawsuit in Lake County Superior Court on Dec. 31 alleging that Eli Lilly conspired with pharmacy benefit managers to artificially inflate insulin list prices through secret rebates, charging roughly $300 to $700 for some insulin products. Lilly said it has taken industry-leading steps to lower insulin costs, including capping out-of-pocket costs at $35 per month and cutting list prices by 70%.
Company response
- Denial — Eli Lilly and Company
  In a statement to WFYI, a company spokesperson said Lilly has taken “industry-leading” steps to lower insulin costs, including capping patient out-of-pocket costs at $35 per month and cutting list prices by 70%.
Source excerpt
- Indiana is suing Indianapolis-based Eli Lilly and Company, accusing the pharmaceutical giant of inflating insulin prices through a coordinated pricing scheme involving secret rebates.
- The lawsuit, filed Dec. 31 in Lake County Superior Court, builds on legal action Rokita took in March 2024 against other drug manufacturers and pharmacy benefit managers over insulin pricing.
- The lawsuit alleges Lilly conspired with pharmacy benefit managers to artificially inflate the sticker prices of insulin.
Source

Pennsylvania sues insulin makers and PBMs over alleged insulin price collusion

Lawsuit filed

Pennsylvania filed a lawsuit against Eli Lilly and Company, Novo Nordisk Inc., Sanofi-Aventis US LLC, and several pharmacy benefit managers (PBMs), alleging that the companies colluded to raise insulin prices. The suit seeks structural changes, restitution, and financial penalties. The allegations concern the pricing of insulin and the roles of both manufacturers and PBMs. The case is a civil action brought by the state; the filing does not itself establish liability, and the claims remain allegations to be resolved through legal proceedings.

Pennsylvania sued Eli Lilly and Co., Novo Nordisk Inc., Sanofi-Aventis US LLC, and several PBMs, alleging that they colluded to raise insulin prices. The lawsuit seeks structural changes, restitution, and financial penalties.

Source excerpt

Last week, Pennsylvania sued a group of pharmaceutical companies and PBMs for allegedly colluding to raise insulin prices unnecessarily.
The pharmaceutical companies included in the Pennsylvania case are Eli Lilly and Co., Novo Nordisk Inc., and Sanofi-Aventis US LLC. Several PBMs are included as defendants, including Express Scripts, Caremark, and Optum RX.
The state’s lawsuit seeks to institute “structural changes to ensure the companies lower costs to fair market prices and enable options for patients,” restitution for Pennsylvanians harmed by the scheme, and payments including financial penalties paid by the companies and the costs of the state’s investigation and lawsuit.

Indiana sues Eli Lilly over alleged insulin price-fixing

Lawsuit filed

Indiana filed a lawsuit in Lake County Superior Court on Dec. 31 alleging that Eli Lilly conspired with pharmacy benefit managers to artificially inflate insulin list prices through secret rebates, charging roughly $300 to $700 for some insulin products. Lilly said it has taken industry-leading steps to lower insulin costs, including capping out-of-pocket costs at $35 per month and cutting list prices by 70%.

Company response

Denial — Eli Lilly and Company
In a statement to WFYI, a company spokesperson said Lilly has taken “industry-leading” steps to lower insulin costs, including capping patient out-of-pocket costs at $35 per month and cutting list prices by 70%.

Source excerpt

Indiana is suing Indianapolis-based Eli Lilly and Company, accusing the pharmaceutical giant of inflating insulin prices through a coordinated pricing scheme involving secret rebates.
The lawsuit, filed Dec. 31 in Lake County Superior Court, builds on legal action Rokita took in March 2024 against other drug manufacturers and pharmacy benefit managers over insulin pricing.
The lawsuit alleges Lilly conspired with pharmacy benefit managers to artificially inflate the sticker prices of insulin.